West Pharmaceutical Services Inc.
West Pharmaceutical Services Appoints Michel Lagarde as New CEO
Summary
West Pharmaceutical Services, Inc. announced on June 1, 2026, the appointment of Michel Lagarde as its new President and Chief Executive Officer, effective August 31, 2026. Lagarde, an experienced healthcare and life sciences executive, will succeed Eric M. Green, who will retire from his roles as President, CEO, and Board Chair on the same date. Lagarde's employment agreement includes an annual base salary of $1,175,000, target annual incentive awards, long-term incentive awards, and one-time inducement equity awards. He will also be eligible for severance benefits and relocation assistance. The Board has also elected Robert F. Friel as the new Board Chair, effective August 31, 2026.
Profitelligence Alerts
Get alerts for WST
Be first to know when West Pharmaceutical Services Inc. files with the SEC.
Filing Categories
Advertisement
About West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.
Official SEC Documents
Advertisement